BBIO Q3 2024 Earnings — BridgeBio Pharma, Inc. Revenue & Financial Results | Market Cap Arena

BBIOBridgeBio Pharma, Inc.

$14B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-33.2% YoY

Gross Profit

$2M78.1% margin

Operating Income

-$192M-7018.7% margin

Net Income

-$162M-5931.2% margin

EPS (Diluted)

$-0.86

QoQ Revenue Growth

+26.0%

Cash Flow

Operating Cash Flow

-$181M

Free Cash Flow

-$182M

Stock-Based Comp.

$27M

Balance Sheet

Total Assets

$665M

Total Liabilities

$1.9B

Stockholders' Equity

-$1.2B

Cash & Equivalents

$266M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$4M	-33.2%
Gross Profit	$2M	$3M	-38.9%
Operating Income	-$192M	-$158M	-21.6%
Net Income	-$162M	-$177M	+8.5%